Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $29.09

Elanco Animal Health Incorporated (NYSE:ELAN) has earned a consensus rating of “Moderate Buy” from the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $29.0909.

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Morgan Stanley raised their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. UBS Group lifted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Citigroup upped their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th.

Elanco Animal Health Trading Up 0.6%

Shares of ELAN stock opened at $22.26 on Friday. The company has a market cap of $11.12 billion, a PE ratio of -54.29, a price-to-earnings-growth ratio of 1.32 and a beta of 1.67. Elanco Animal Health has a 1 year low of $16.89 and a 1 year high of $27.98. The stock’s 50 day simple moving average is $24.67 and its two-hundred day simple moving average is $24.07. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the previous year, the company posted $0.26 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts predict that Elanco Animal Health will post 1.12 earnings per share for the current year.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the acquisition, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 24,082 shares of company stock worth $533,542. Insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its holdings in Elanco Animal Health by 5.9% in the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares in the last quarter. Sapient Capital LLC increased its holdings in shares of Elanco Animal Health by 0.3% during the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock valued at $3,164,000 after acquiring an additional 420 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock valued at $1,631,000 after purchasing an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its stake in Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after purchasing an additional 428 shares in the last quarter. Finally, Meeder Advisory Services Inc. boosted its stake in Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after purchasing an additional 510 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.